AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03720288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
Trial: NCT01320592
Drug: PD0332991
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03408184
Drug: Lumbar paravertebral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
Trial: NCT02429791
Drug: DTG 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Trial: NCT02429791
Drug: RPV 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Trial: NCT03376659
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg orally twice a day, Monday - Friday Weekly
Trial: NCT01280643
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01280643
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01280643
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00756782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
Trial: NCT00256178
Drug: Lapaquistat acetate and simvastatin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Trial: NCT04772508
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
Trial: NCT00884221
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Trial: NCT00256178
Drug: Lapaquistat acetate and simvastatin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Trial: NCT00256178
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
Trial: NCT03344679
Drug: Adenosine 12mg
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 12 mg for PECS block
Trial: NCT00252655
Drug: Rapamune and Prograf
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924287
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
Trial: NCT02002221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of vildagliptin 50 mg twice daily
Trial: NCT01466985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for 7 days.
Trial: NCT00990834
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg PO daily for one to eight months.
Trial: NCT01719835
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2 IV every 21 days
Trial: NCT01719835
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m2 IV every 21 days
Trial: NCT01719835
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg PO Days 1-5 every 21 days
Trial: NCT01093118
Drug: TMI-358
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micro implant monthly x 3
Trial: NCT03224182
Drug: Qapzola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qapzola administered by the intravesical route.
Trial: NCT03224182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qapzole-matching placebo administered by the intravesical route.
Trial: NCT00506259
Drug: dTR Melatonin (NIH CC PDS)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00506259
Drug: Melatonin CR
RxNorm normalized name: Melatonin CR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269566
Drug: HollisterStier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
Trial: NCT02269566
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of normal saline 3 injections into an inguinal lymph node
Trial: NCT01687920
Drug: BAY94-8862 (1.25mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687920
Drug: BAY94-8862 (2.5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687920
Drug: BAY94-8862 (5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687920
Drug: BAY94-8862 (7.5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687920
Drug: BAY94-8862 (10mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02103777
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
Trial: NCT02052687
Drug: LFX453 H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFX453 high dose cream 1
Trial: NCT02052687
Drug: LFX453 H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFX453 high dose cream 2
Trial: NCT02052687
Drug: LFX453 L2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFX453 low dose cream 2
Trial: NCT02052687
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream 1
Trial: NCT02052687
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream 2
Trial: NCT01235520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses, once a day for 52 weeks
Trial: NCT01235520
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose level 1, once a day for 52 weeks
Trial: NCT01235520
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose level 2, once a day for 52 weeks
Trial: NCT03087890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 tablets placebo daily for 48 weeks
Trial: NCT00357019
Drug: N-acetyl-aspartyl-glutamate (NAAXIA Sine)
RxNorm normalized name: acetyl glutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02563938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786395
Drug: UF-021
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04172701
Drug: Long-acting Muscarinic Antagonists (LAMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT04172701
Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT02681913
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group receives intermittent warm blood cardioplegia enriched with adenosine
Trial: NCT02227394
Drug: Symbicort® Turbohaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
Trial: NCT00293436
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01002742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Trial: NCT01545583
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT01922115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01925950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01998919
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
Trial: NCT02209974
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00746590
Drug: Prolarix (tretazicar co-administered with caricotamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Trial: NCT02643732
Drug: Placebo (Over-encapsulated tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Trial: NCT04190004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Trial: NCT01423916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-34712 placebo
Trial: NCT02538185
Drug: Vaccin rabique Pasteur®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride (NaCl) 0,9%; B. Braun
Trial: NCT03881306
Drug: D-TACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-TACE with CalliSpheres-Oxaliplatin
Trial: NCT03414294
Drug: K-755 Part A (SAD)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
Trial: NCT03414294
Drug: Placebo Part A (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Trial: NCT03414294
Drug: K-755 Part B (MAD)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Trial: NCT03414294
Drug: Placebo Part B (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Trial: NCT03414294
Drug: K-755 Part C (FE)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Trial: NCT03414294
Drug: K-755 Part D (FE)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Trial: NCT03414294
Drug: K-755 Part E (MAD)
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Trial: NCT03414294
Drug: Placebo Part E (MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Trial: NCT03313336
Drug: EMLA test patch
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
Trial: NCT03313336
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
Trial: NCT05241145
Drug: IVMED-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
Trial: NCT00624754
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose 2 puffs b.i.d for 1 month
Trial: NCT03921177
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preconception to 12-weeks gestation: identical tablet
Trial: NCT02522650
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg twice a day for 8 weeks
Trial: NCT03246555
Drug: Fimasartan or Fimasartan/Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Trial: NCT03246555
Drug: Perindopril or Perindopril/Indapamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
Trial: NCT00626028
Drug: Nitric Oxide for inhalation
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
Trial: NCT02282176
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin IV 10mg/kg daily for 10 days
Trial: NCT02282176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin placebo (5% Dextrose) daily for 10 days
Trial: NCT00626028
Drug: Nitric Oxide plus Oxygen
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
Trial: NCT00831779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Trial: NCT00289354
Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg)
RxNorm normalized name: biotin / chromium picolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00372281
Drug: Cliavist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Trial: NCT00554385
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
Trial: NCT00696748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 mL intramuscular
Trial: NCT02506842
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
Trial: NCT01982240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets QD for 12 weeks
Trial: NCT00813618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Trial: NCT00813618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Trial: NCT02384759
Drug: LV5FU2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00813618
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Trial: NCT03224585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days
Trial: NCT02169414
Drug: BIA 9-1067 5 mg
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC, Opicapone
Trial: NCT02169414
Drug: BIA 9-1067 25 mg
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC, Opicapone
Trial: NCT02169414
Drug: levodopa/carbidopa 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate (standard) release levodopa/carbidopa 100/25
Trial: NCT02169414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC, Placebo
Trial: NCT02169414
Drug: levodopa/benserazide 100/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate (standard) release levodopa/benserazide
Trial: NCT00774020
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg, i.v. single dose
Trial: NCT03762447
Drug: INCB086550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
Trial: NCT01992562
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01753401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
Trial: NCT01753401
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
Trial: NCT00250185
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00316238
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no